Compare CRK & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRK | PBLS |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 1995 | 2026 |
| Metric | CRK | PBLS |
|---|---|---|
| Price | $13.73 | $40.44 |
| Analyst Decision | Hold | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $22.20 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 351.8K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 288.16 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $555,231,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.91 | N/A |
| P/E Ratio | $33.85 | ★ N/A |
| Revenue Growth | ★ 32.11 | N/A |
| 52 Week Low | $12.12 | $25.56 |
| 52 Week High | $28.10 | $41.35 |
| Indicator | CRK | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 71.58 |
| Support Level | $12.56 | $34.78 |
| Resistance Level | $14.25 | N/A |
| Average True Range (ATR) | 0.52 | 2.45 |
| MACD | 0.04 | 0.45 |
| Stochastic Oscillator | 58.90 | 92.65 |
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.